What is Modulim?
Modulim is at the forefront of optical imaging, leveraging spatial frequency domain imaging (SFDI) to provide clinicians with critical insights into compromised circulation. This technology offers a non-invasive method for assessing tissue perfusion, which is vital for diagnosing and managing a range of medical conditions. The company's solutions aim to enhance diagnostic accuracy and improve patient outcomes by delivering objective, quantitative data that traditional imaging methods may not capture. Modulim's commitment to pioneering these advanced imaging techniques positions it as a key player in the medical technology sector, particularly in areas requiring precise circulatory assessment.
How much funding has Modulim raised?
Modulim has raised a total of $12.7M across 5 funding rounds:
Angel/Seed
$500K
Private Equity
$2M
Series A
$2.9M
Series B
$7M
Debt
$350K
Angel/Seed (2016): $500K with participation from The Cove Fund
Private Equity (2017): $2M, investors not publicly disclosed
Series A (2017): $2.9M supported by Grey Sky Venture Partners, Mitsubishi UFJ Capital Co, Ltd, and Hamamatsu
Series B (2019): $7M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Key Investors in Modulim
Grey Sky Venture Partners
Grey Sky Venture Partners is a venture capital firm that likely focuses on early-stage technology companies, providing strategic guidance and capital to foster growth and market entry.
Mitsubishi UFJ Capital Co, Ltd
Mitsubishi UFJ Capital Co, Ltd is a Japanese investment firm with a strong track record of financing companies and facilitating their access to the Japanese market, often supporting those looking for public offerings.
Hamamatsu
Hamamatsu is a global leader in photonics technology, providing advanced optical sensors and systems that are crucial for innovation in medical, industrial, and scientific fields.
What's next for Modulim?
With the recent infusion of $350K in a major strategic investment, Modulim is poised for accelerated growth and technological advancement. This substantial backing, part of its overall $12.7M in capital, suggests a strong market validation and confidence from investors in Modulim's vision and capabilities. The company is likely to focus on scaling its operations, expanding its product development pipeline, and increasing market penetration. Further research and development into SFDI applications for various clinical scenarios, alongside potential strategic partnerships, are anticipated as Modulim solidifies its position as a leader in advanced optical diagnostics.
See full Modulim company page
